Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vYF versus Stamaril immunogenicity and safety study in adults
2020-005566-33Phase 2Active
- Sponsor
- Sanofi
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SP0218 in yellow fever (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of participants in EU with seroconversion to yellow fever virus in the yellow fever-naive population. Started Apr 2021; status: active.
02
Drugs
SP0218
03
Conditions
yellow fever
Beyond the preview
Go deeper on 2020-005566-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005566-33.